Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29798814 | 0.77 | AKR1B1 (0.42) | AKR1B1 | |
| SCHEMBL20512155 | 0.77 | AKR1B1 (0.42) | AKR1B1 | |
| SCHEMBL20512217 | 0.72 | HSPA5 (0.48) | CYP3A4AKR1B1KDM4ETP53MAPT | |
| SCHEMBL20512081 | 0.70 | PTGS2 (0.46) | BACE1KDM4EHSD17B10 | |
| SCHEMBL2612551 | 0.65 | PTGS2 (0.41) | KDM4EHSD17B10 | |
| SCHEMBL29852860 | 0.64 | AKR1B1 (0.55) | AKR1B1MTNR1AMTNR1B | |
| SCHEMBL5370276 | 0.64 | AKR1B1 (0.55) | AKR1B1MTNR1AMTNR1B | |
| SCHEMBL11926974 | 0.64 | L3MBTL1 (0.45) | KDM4EHSD17B10 | |
| SCHEMBL28302378 | 0.64 | SMN1; SMN2 (0.42) | KDM4EGAAHTTHSD17B10 | |
| SCHEMBL1009146 | 0.62 | PKM (0.58) | AKR1B1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201218-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20210009580-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20200297733-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2020-09-24 | — | — | US | disclosed |
| US-10722521-B2 | Beta-lactamase inhibitors and uses thereof | ARIXA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200046724-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-10500211-B2 | Beta-lactamase inhibitors and uses thereof | ARIXA PHARMACEUTICALS, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| US-10280161-B2 | Aztreonam derivatives and uses thereof | ARIXA PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20190100516-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-04-04 | — | — | US | disclosed |
| US-20190022102-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280161-B2 | Aztreonam derivatives and uses thereof | MGAM, ABCG2, SI | BACE1 109/4885CYP3A4 144/4885AKR1B1 1122/4885 |
| US-20190022102-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | MGAM, LCT, CMBL | BACE1 24/4885CYP3A4 509/4885AKR1B1 2207/4885 |
| US-20190100516-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | MGAM, ABCG2, SI | BACE1 109/4885CYP3A4 144/4885AKR1B1 1122/4885 |
| US-20230201218-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | GAA, LCT, MGAM | BACE1 24/4885CYP3A4 385/4885AKR1B1 1770/4885 |
| US-20210009580-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | MGAM, ABCG2, SI | BACE1 109/4885CYP3A4 144/4885AKR1B1 1122/4885 |
| US-20200046724-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | GAA, MGAM, LCT | BACE1 34/4885CYP3A4 430/4885AKR1B1 1772/4885 |
| US-20200297733-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | GAA, LCT, MGAM | BACE1 24/4885CYP3A4 385/4885AKR1B1 1770/4885 |
| US-10722521-B2 | Beta-lactamase inhibitors and uses thereof | GAA, LCT, MGAM | BACE1 24/4885CYP3A4 385/4885AKR1B1 1770/4885 |
| US-10500211-B2 | Beta-lactamase inhibitors and uses thereof | GAA, LCT, MGAM | BACE1 24/4885CYP3A4 385/4885AKR1B1 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.